In a settlement announced Friday, Mylan, Inc., the maker of EpiPens, will shell out $465 million to the US Department of Justice and other federal agencies to brush aside any questions about its Medicaid rebates.

As Ars reported last week, the Centers for Medicare and Medicaid Services (CMS) announced that, by misclassifying EpiPens for years, Mylan has been stiffing federal and state governments out of millions of dollars’ worth of rebates. The CMS said that it had notified Mylan of the mistake “on multiple occasions” since 2007, when the company bought the EpiPen from Merck.

In the meantime, Mylan hiked the price of the life-saving devices on 15 separate occasions, reaching an increase of more than 500 percent. An EpiPen two-pack now goes for more than $600, while a nearly identical single pen was around just $50 in 2007. The steep rise in price has drawn outrage and scorn from the public and lawmakers.

With the $465 million settlement, Mylan hopes to improve its public image. However, as part of the agreement, the company said it would not fess up to any wrongdoing.

In a statement, Mylan CEO Heather Bresch said:

This agreement is another important step in Mylan's efforts to move forward and bring resolution to all EpiPen Auto-Injector related matters. The agreement is in addition to the significant steps Mylan has taken in relation to EpiPen Auto-Injector over the past several weeks, including the unprecedented, pending launch of a generic version of EpiPen Auto-Injector and expansion of our patient access programs for this product. Entering into this settlement is the right course of action at this time for the Company, its stakeholders and the Medicaid program.

The disagreement between the CMS and Mylan centers around how to classify EpiPens under the Medicaid Drug Rebate Program, which requires drug makers to offer the government rebates if their drugs are covered by Medicaid and Medicare. According to the CMS, EpiPen, which currently has no generic version and is under patent protection, is clearly a brand name, single-source drug. As such, the Medicaid Drug Rebate Program requires Mylan pay a rebate of 23.1 percent to the government. Also, Mylan would be required to cough up extra rebates any time it raised the price of its brand name drug at a rate higher than inflation, which it did—15 times.

But, Mylan reported to the CMS that the EpiPen is a generic. As such, the company has only been paying 13 percent rebates and not shelling out anything after price hikes.

Although the government has not released an estimated total of how much Mylan underpaid, the Minnesota Department of Health estimates that Mylan cost that state alone $4.3 million just in 2015.

Under the terms of the settlement with the DOJ, Mylan will be clear of any liability claims by the federal and state governments related to EpiPens classification and rebates.